The U.S. Food and Drug Administration (FDA) has granted fast track designation to PLN-74809, now in a Phase 2 clinical trial, as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is intended to help speed the development of treatments aiming to address unmet medical needs for serious…
News
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit its enrollment target for the Phase 2b trial — now under a revised protocol — testing its investigational inhaled therapy GB0139 for idiopathic pulmonary fibrosis (IPF). Galecto had resumed trial…
A new multiphase educational collaboration seeks to slash the time it takes for many people to receive a diagnosis of interstitial lung disease (ILD), including pulmonary fibrosis (PF). The Three Lakes Foundation and the American College of Chest Physicians (CHEST) will work together to heighten disease awareness among healthcare…
The first patient has been enrolled in a U.S. clinical trial evaluating the efficacy and safety of a new artificial intelligence-based app, called Almee, that’s designed to treat anxiety in people with idiopathic pulmonary fibrosis (IPF). Almee, developed by Vicore Pharma, is an experimental digital therapy that delivers…
Organizers say that just a few tickets are still available for this year’s rendition of the Broadway Belts for PFF! fundraiser, benefitting the Pulmonary Fibrosis Foundation (PFF). The annual event, slated for April 29 at the Edison Ballroom in New York City, again will bring together an array of…
Enrollment is now complete in ZEPHYRUS-1, a Phase 3 trial of pamrevlumab, an investigational treatment for idiopathic pulmonary fibrosis (IPF), the therapy’s developer, FibroGen, announced. The randomized, placebo-controlled trial (NCT03955146) now includes 356 IPF patients across 144 sites worldwide. It aims to evaluate the safety and efficacy…
Bridge Biotherapeutics has entered an exclusive in-licensing agreement with Shaperon to develop BBT-209, an investigational therapy for idiopathic pulmonary fibrosis (IPF). “We hope that BBT-209 will become a breakthrough therapy for patients with IPF, who are currently lacking treatment options,” Seung-Yong Seong, MD, PhD and Myung-Sea Lee, MD,…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues in a nod to its increased use during the ongoing COVID-19 pandemic. NORD’s report card project began seven…
